Poolbeg Pharma identifies potential new drug candidates from its RSV AI programme

Poolbeg Pharma plc (LON:POLB), a leading infectious disease focused biopharmaceutical company, has announced that it has successfully identified potential new drug candidates from its Respiratory Syncytial Virus artificial intelligence Programme with OneThree Biotech, Inc.

Since initiating the collaboration in February 2022, Poolbeg’s scientific team has worked closely with OneThree to build a tailored AI approach that leverages Poolbeg’s unique RSV human challenge trial data in order to identify disease-relevant biological pathways and potential drug targets. Based on those newly discovered drug targets, the collaboration has now identified a number of promising drug candidates to rapidly bring forward to lab-based validation to determine the full potential of these assets.

The Company has prioritised compounds with existing Phase I clinical data and which could, if successfully validated, be repositioned as novel treatments for RSV infection. Candidates with solid safety and pharmacodynamic data in humans are well positioned to rapidly enter a clinical trial to generate early human efficacy data for RSV. This is in line with Poolbeg’s efficient, capital light clinical development strategy that is at the core of its ambitious growth model.  

RSV, which inflames the smallest airways of the lungs, usually sends an average of 58,000-80,000 children under the age of 5 to hospital each year in the US alone, according to the US Centers for Disease Control and Prevention (CDC). RSV can also be dangerous for adults over the age of 65, resulting in around 177,000 hospitalisations per year in the United States alone. The current cold and flu season commenced about two months earlier than anticipated and already rivals some of the worst seasons on record with RSV hospitalising young children in the United States and Europe at an alarming rate. Public health officials have been warning for weeks that a “tripledemic” of SARS-CoV-2, influenza and RSV would strain an already weary healthcare system. RSV has made so many young children ill this fall that weekly paediatric hospitalisations in the US are the highest recorded.

Jeremy Skillington, PhD, CEO of Poolbeg Pharma said: “In the past few months, RSV has been sending children to hospital at alarming rates in the United States and Europe. As paediatric units fill beyond capacity, and our healthcare systems contend with a ‘tripledemic’ of RSV, influenza and SARS-CoV-2, the need for better treatments has never been so urgent.

We’re impressed with the quality of work executed so far with OneThree leveraging their AI expertise to present new drug potential candidates from our unique human challenge trial data which Poolbeg will now optimise for further development in RSV, the only one of the three main respiratory illnesses for which there are not yet any approved vaccines and where treatment options are limited.”

Neel S. Madhukar, PhD, co-founder and CEO of OneThree Biotech, said: We are very pleased to be working with Poolbeg and to have the opportunity to deploy the ATLANTIS platform to complete the first ever AI-driven analysis of RSV disease progression data. I am delighted that Poolbeg’s unique dataset combined with OneThree’s externally validated platform have now delivered new actionable insights surrounding disease biology and drug discovery that can bring much needed treatment options for both the young and the elderly; the most vulnerable to RSV infection.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn

More articles like this

The age of AI has begun

Health I see several ways in which AIs will improve health care and the medical field. For one thing, they’ll help health-care workers make the most of their time by taking care of certain tasks for them—things like

Poolbeg Pharma continues expansion and diversification of pipeline

Poolbeg Pharma Plc (LON:POLB, OTCQB: POLBF) a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, has announced its audited results for the year ended 31 December 2022. Financial & Corporate Highlights –       Well

New results for severe influenza and inflammatory conditions

Poolbeg Pharma, an infectious disease-focused biopharmaceutical company, has announced data from the bacterial lipopolysaccharide (‘LPS’) human challenge trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the unmet medical need arising from

Poolbeg Pharma releases positive data from influenza trial

Poolbeg Pharma has released new data from a human challenge trial that shows its treatment has strong potential in dampening inflammation in blood and tissues in influenza and other viral infections. POLB 001 showed success in reducing multiple markers

Poolbeg Pharma granted patent by USPTO for POLB 001

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF),  a leading infectious disease focused biopharmaceutical company, has announced that further to its announcement on 4 October 2022, it has been granted a patent by the US Patent and Trademark Office (USPTO) for methods of treating hypercytokinaemia

Positive results from Poolbeg Pharma’s human challenge trial

Poolbeg Pharma – a company focused on developing infectious disease therapies – has announced data from its bacterial lipopolysaccharide (LPS) human challenge trial for POLB 001. The treatment is a viral strain agnostic, small molecule immunomodulator which is

SLAS2023: We have the building blocks, onto the building

In the time that has passed since SLAS2022 in Boston, USA, the drug discovery industry has had to deal with all manner of external obstacles, from the war in Ukraine, to how Brexit has changed the world’s relationship

The small drug firms set to benefit from RSV vaccines

Here’s an investment idea that starts with large blue-chip companies, but has significant trickle-down potential to at least three smaller, growth companies listed in the UK. Chances are RSV, or respiratory syncytial virus, which has symptoms similar to

Poolbeg Pharma Investment Case

Poolbeg Pharma (LON:POLB / OTCQB:POLBF) Investment Case with CEO Jeremy Skillington. Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company with a unique capital light model. The company is focus on targeting the significant global medical need to treat

AI continues to gain momentum in the biopharmaceutical industry in 2023

While the biopharmaceutical industry has been impacted and pressured by various factors such as the Covid-19 pandemic, inflation, the Ukraine-Russia war, ongoing supply chain issues, and a challenging economic environment, collaboration between pharma companies and emerging technologies providers

Elaine Sullivan on International Day of Women & Girls in Science

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Donegal man hopes to raise $1 billion in Nasdaq launch

A Donegal man hopes to raise one billion dollars when his latest venture launches on New York’s Nasdaq. Poolbeg Pharma is planning to list on the stock exchange as chairman Cathal Friel (58), from Creeslough, eyes another $1bn

The race to supercharge cancer-fighting T cells

CAR-T therapies capitalize on the activities of T cells, the immune system’s natural hunters that prowl through the body looking for things that don’t belong. Foreign cells, or those infected with a virus, express unusual proteins that serve

AI continues to gain momentum in the biopharmaceutical industry in 2023

While the biopharmaceutical industry has been impacted and pressured by various factors such as the Covid-19 pandemic, inflation, the Ukraine-Russia war, ongoing supply chain issues, and a challenging economic environment, collaboration between pharma companies and emerging technologies providers

No more posts to show